EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children

Sigrid van der Veen iD, Bart J Biemond iD, Marjon H Cnossen iD, Pablo Bartolucci iD, Maria P Boaro iD, Betzabel Cajiao Garcia iD, Raffaella Colombatti iD, M D'Agnolo iD, Karin Fijnvandraat iD, Anna Collado Gimbert iD, Amira Idrizovic iD, Petros Kountouris iD und 15 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Sigrid van der Veen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Net…. Hauptthemen laut MEDLINE: Hydroxyurea, Anemia, Sickle Cell, Antisickling Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GenoMed4All, ERN-EuroBloodNet, Agios Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydroxyurea (HU) is the most widely prescribed disease‐modifying treatment in sickle cell disease (SCD), though treatment responses vary due to metabolism and adherence. We examined HU blood levels and treatment response in patients with homozygous sickle cell disease (HbSS). We measured HU in whole blood of 955 SCD patients enrolled in GenoMed4All using mass spectrometry. HU detection was defined as Z‐score > 2.5 relative to untreated healthy controls. Among HbSS patients not receiving recent transfusion therapy ( n = 539), HU was detected in 39% (143/369) of HU‐prescribed patients ≥ 10 years (median age 31.8 [10.0–69.9]). In only 24% (23/109) of young patients (< 10 years, median age 5.9 [1.2–9.9]), HU was detected, despite comparable HU dosing (18.8 vs. 20.3 mg/kg/day). Detectable HU was associated with increased MCV ( p < 0.001), and in patients ≥ 10 years also with increased HbF, despite low HbF (< 10%) in 25%. Neutropenia occurred in 8.0% of patients with detectable HU, 4.5% with undetected HU. Only one patient had severe neutropenia (< 0.5 × 10e9/l). In young patients, neutropenia occurred in 1.4% with undetected HU, and in 8.7% with detected HU. This is the largest study to date that reports data on HU levels in HbSS patients. Most HU‐prescribed patients, particularly young patients, had undetectable HU levels. Low MCV, HbF, and absent toxicity in children and limited toxicity in adults suggest that treatment for patients with undetectable HU is suboptimal. These findings warrant the need to optimize dosing and adherence to improve treatment in SCD, especially in young patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxyureaAnemia, Sickle CellAntisickling AgentsHumansChildFemaleChild, PreschoolMaleAdolescentAdultInfantFetal HemoglobinYoung AdultMiddle AgedNeutropenia

Substanzen

HydroxyureaFetal HemoglobinAntisickling Agents

Autor:innen und Institutionen

  • Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Section Metabolic Diagnostics, Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Hematology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Department of Pediatric Hematology and Oncology, Erasmus MC - Sophia Children's Hospital, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • University Paris-Est-Créteil, IMRB, Inserm U955, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Creteil, France.
  • UOC Oncoematologia Pediatrica, Azienda Ospedale-Università Padova, Padua, Italy.

ORCID-Profile: Sigrid van der Veen, Bart J Biemond, Marjon H Cnossen, Pablo Bartolucci, Maria P Boaro, Betzabel Cajiao Garcia, Raffaella Colombatti, M D'Agnolo, Karin Fijnvandraat, Anna Collado Gimbert, Amira Idrizovic, Petros Kountouris, Mar Mañú-Pereira, Elisabetta Mezzalira, Mariane de Montalembert, Erfan Nur, A Pham Hung D' Alexandry D'Orengiani, Tiziana Sanavia, Saskia E M Schols, Marissa J M Traets, Minke A E Rab, Sara I Reidel, Anita W Rijneveld, Nanda M Verhoeven-Duif, Judith J M Jans, Eduard J van Beers

Förderung

  • GenoMed4All
  • ERN-EuroBloodNet
  • Agios Pharmaceuticals
  • Novo Nordisk

Zitieren

APA

van der Veen, S., Biemond, B. J., Cnossen, M. H., Bartolucci, P., Boaro, M. P., Garcia, B. C., Colombatti, R., D'Agnolo, M., Fijnvandraat, K., Gimbert, A. C., Idrizovic, A., Kountouris, P., Mañú-Pereira, M., Mezzalira, E., de Montalembert, M., Nur, E., D'Orengiani, A. P. H. A., Sanavia, T., Schols, S. E. M., …, & van Beers, E. J. (2026). Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children. American Journal of Hematology. https://doi.org/10.1002/ajh.70429

Vancouver

van der Veen S, Biemond BJ, Cnossen MH, Bartolucci P, Boaro MP, Garcia BC, et al. Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children. American Journal of Hematology. 2026. doi:10.1002/ajh.70429

BibTeX
@article{vanderVeen2026,
  author = {van der Veen, Sigrid and Biemond, Bart J and Cnossen, Marjon H and Bartolucci, Pablo and Boaro, Maria P and Garcia, Betzabel Cajiao and Colombatti, Raffaella and D'Agnolo, M and Fijnvandraat, Karin and Gimbert, Anna Collado and Idrizovic, Amira and Kountouris, Petros and Mañú-Pereira, Mar and Mezzalira, Elisabetta and de Montalembert, Mariane and Nur, Erfan and D'Orengiani, A Pham Hung D' Alexandry and Sanavia, Tiziana and Schols, Saskia E M and Traets, Marissa J M and Rab, Minke A E and Reidel, Sara I and Rijneveld, Anita W and Zaouali, Yosr and Verhoeven-Duif, Nanda M and Jans, Judith J M and van Beers, Eduard J},
  title = {Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70429}
}
Kostenlos starten →